Norton Neuroscience Institute selected to pilot national Brain Health Navigator program
Norton Neuroscience Institute is one of six sites nationwide chosen to pilot a new Brain Health Navigator program aimed at creating a worldwide model to prevent, diagnose and treat Alzheimer’s disease. The program — funded […]
View more
Treating side effects and other lessons learned while administering Alzheimer’s drug lecanemab
A recent study published in the The Journal of Prevention of Alzheimer’s Disease provides detailed insight into clinicians’ and patients’ initial experience with lecanemab, the first Food and Drug Administration-approved antiamyloid monoclonal antibody infusion proven [...]
View more
New provider joins Norton Neuroscience Institute Hussung Family Multiple Sclerosis Center
David A. Robertson, M.D., neurologist and neuroimmunologist, has joined Norton Neuroscience Institute Hussung Family Multiple Sclerosis Center. Dr. Robertson is originally from McPherson, Kansas. He graduated from the University of Kansas School of Medicine in 2004 […]
View more
Norton Neuroscience Institute to acquire groundbreaking focused ultrasound technology
Norton Neuroscience Institute will be the first and only facility in Kentucky to offer MRI-guided high-frequency focused ultrasound for essential tremor and tremor-dominant Parkinson’s disease. This life-changing treatment has been shown to dramatically improve tremor symptoms for patients starting […]
View more
45% of dementias can be prevented with some easily implemented strategies
A study showed that about 45% of dementias are preventable through lifestyle modifications. The societal impacts of this research include reducing financial burdens on the health care system, improving social participation and population health, and […]
View more
New Alzheimer’s drugs showing success slowing disease progression, especially when treated early
New monoclonal antibody therapies targeting beta-amyloid deposition in the brain have shown success in slowing the progression of Alzheimer’s disease, though the risk of serious side effects necessitates careful evaluation and discussion before initiating treatment.. [...]
View more
Advanced treatments for neuromuscular disorders
Neuromuscular disorders are conditions that affect the structure and function of the peripheral nervous system, as well as all motor and sensory nerves. The predominant symptom of this group of disorders is progressive muscle weakness. […]
View more
New provider joins Norton Neuroscience Institute Memory Center team
Physician assistant Kendall M. Wasz, PA-C, has joined the memory care team at Norton Neuroscience Institute. Kendall holds Master of Science degree in physician assistant studies from the University of Kentucky, Lexington, and earned her […]
View more
Norton Research Institute unveils state-of-the-art research laboratory
Norton Research Institute will expand research efforts with the unveiling of the new Norton Research Institute Clinical & Translational Research Laboratory. The 7,200-square-foot facility, located inside Norton Healthcare Pavilion in downtown Louisville, will afford ample space […]
View more
Ways to make prescribing controlled substances safer
Safer controlled substance prescribing begins with a thorough patient workup, an appropriate diagnosis and a comprehensive treatment plan, according to Kelly C. Cooper, M.D., an addiction medicine specialist with Norton Behavioral Medicine. “We just tend [...]
View more
Sciatic neuropathy case study: 4-centimeter tumor discovered on sciatic nerve
The patient A 64-year-old woman tripped after “missing a step,” fracturing her left tibial plateau and resulting in deformity of the joint. This was managed conservatively, with a leg brace removing weight from the extremity. [...]
View more
Updated information on lecanemab infusions for mild cognitive impairment and Alzheimer’s
In 2023, the Food and Drug Administration (FDA) approved lecanemab (brand name Leqembi) for the treatment of Alzheimer’s disease. Lecanemab is the first widely used medication in a new class of anti-amyloid agents for the […]
View more